Zentalis Pharmaceuticals sets IPO terms, to be valued at up to $592 million

Zentalis Pharmaceuticals (ZNTL), set terms of its initial public offering, in which the biopharmaceutical company developing cancer treatments is expected to raise up to…

$137.7 million.

Zentalis is offering 7.65 million shares in the IPO, which is expected to price between $16 and $18 a share.

That would give the company a market capitalization of up to $591.7 million.

The stock is expected to list on the Nasdaq exchange under the ticker symbol “ZNTL.”

The lead underwriters are Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities.

The company recorded a net loss of $45.7 million in 2019 on no revenue, after a loss of $21.1 million on $14,000 in revenue in 2018.

Zentalis is looking to go public at…

Continue reading at MARKETWATCH.com


You May Also Like

About the Author: Admin